GeneDx (NASDAQ:WGS – Free Report) had its price target raised by Craig Hallum from $43.00 to $46.00 in a research note released on Wednesday, Benzinga reports. They currently have a buy rating on the stock.
A number of other research analysts also recently commented on the company. Jefferies Financial Group began coverage on GeneDx in a report on Monday, June 3rd. They issued a hold rating and a $21.00 price objective on the stock. BTIG Research upped their price objective on GeneDx from $19.00 to $35.00 and gave the company a buy rating in a research note on Wednesday, June 26th. The Goldman Sachs Group raised their target price on shares of GeneDx from $28.00 to $32.00 and gave the stock a neutral rating in a research note on Wednesday. Finally, TD Cowen increased their target price on GeneDx from $14.00 to $24.00 and gave the stock a buy rating in a research note on Tuesday, April 30th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, GeneDx currently has a consensus rating of Moderate Buy and a consensus price target of $38.80.
Read Our Latest Stock Analysis on WGS
GeneDx Price Performance
Insider Buying and Selling
In other GeneDx news, Director Casdin Capital, Llc acquired 100,000 shares of GeneDx stock in a transaction dated Monday, June 3rd. The stock was acquired at an average cost of $20.82 per share, for a total transaction of $2,082,000.00. Following the completion of the transaction, the director now owns 3,063,509 shares in the company, valued at approximately $63,782,257.38. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, major shareholder Opko Health, Inc. sold 88,839 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $33.50, for a total transaction of $2,976,106.50. Following the completion of the transaction, the insider now owns 2,984,564 shares of the company’s stock, valued at $99,982,894. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Casdin Capital, Llc acquired 100,000 shares of the stock in a transaction dated Monday, June 3rd. The stock was acquired at an average cost of $20.82 per share, for a total transaction of $2,082,000.00. Following the purchase, the director now directly owns 3,063,509 shares in the company, valued at $63,782,257.38. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 175,804 shares of company stock valued at $3,771,670 and have sold 490,343 shares valued at $15,701,354. Corporate insiders own 28.10% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. Oracle Investment Management Inc. increased its position in GeneDx by 531.7% in the 1st quarter. Oracle Investment Management Inc. now owns 1,126,607 shares of the company’s stock worth $10,286,000 after purchasing an additional 948,253 shares during the last quarter. Assenagon Asset Management S.A. bought a new stake in shares of GeneDx in the 2nd quarter valued at approximately $9,575,000. Gagnon Securities LLC increased its holdings in GeneDx by 59.3% in the first quarter. Gagnon Securities LLC now owns 556,305 shares of the company’s stock worth $5,079,000 after buying an additional 207,027 shares during the last quarter. Decheng Capital LLC bought a new position in GeneDx during the fourth quarter valued at approximately $285,000. Finally, Gagnon Advisors LLC lifted its stake in GeneDx by 41.6% in the first quarter. Gagnon Advisors LLC now owns 211,393 shares of the company’s stock valued at $1,930,000 after acquiring an additional 62,059 shares during the last quarter. 61.72% of the stock is owned by hedge funds and other institutional investors.
About GeneDx
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Recommended Stories
- Five stocks we like better than GeneDx
- What Are Dividends? Buy the Best Dividend Stocks
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- Comparing and Trading High PE Ratio Stocks
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
- How to buy stock: A step-by-step guide for beginners
- Intel Loses a Quarter of Its Value After Horrible Earnings Report
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.